IGC Pharma announces Q2 earnings per share of 2 cents, unchanged from last year.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 17 2025
0mins
Q2 Revenue Decline: IGC Pharma reported a Q2 revenue of $191,000, a significant drop from $412,000 in the same period last year.
Strategic Focus: CEO Ram Mukunda highlighted the company's dual strategy in clinical trials and AI, emphasizing progress in their Alzheimer's program and improved manufacturing operations.
Enrollment Milestone: The Alzheimer's program has surpassed the 50% enrollment mark, showcasing IGC's operational focus and commitment to advancing their clinical trials.
Recognition of AI Platform: The NIA award validates IGC's AI platform as a valuable tool for accelerating Alzheimer's diagnostics, indicating potential for future growth and shareholder value.
Analyst Views on IGC
Wall Street analysts forecast IGC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IGC is 4.75 USD with a low forecast of 4.75 USD and a high forecast of 4.75 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.301
Low
4.75
Averages
4.75
High
4.75
Current: 0.301
Low
4.75
Averages
4.75
High
4.75
About IGC
IGC Pharma, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) to develop treatments for Alzheimer's and metabolic disorders. The Company's lead asset, IGC-AD1, is a cannabinoid-based therapy is in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The Company’s pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The Company integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. It is also developing a Multimodal Interpretable Transformer for Alzheimer’s Disease (MINT-AD). MINT-AD leverages diverse data sources, including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
